Cory Iverson
Impact in
- Nephrology top 5%
- Gout, Hyperuricemia, Uric Acid
Papers in
-
- Melanoma and MAPK Pathways 5
- Angiogenesis and VEGF in Cancer 1
- Ubiquitin and proteasome pathways 1
- Oncology 4
- Co-authors
- Jeffrey N. Miner (8 shared papers)Li‐Tain Yeh (7 shared papers)Stephanie Chu (1 shared paper)John R. Yates (1 shared paper)Barry Quart (3 shared papers)Scott Anderson (1 shared paper)Stephen R. Fairclough (1 shared paper)Ted Powers (1 shared paper)
- Journals
- Clinical Cancer Research (2 papers)Arthritis Research & Therapy (2 papers)Molecular Cancer Therapeutics (2 papers)Journal of Clinical Oncology (1 paper)Journal of Biological Chemistry (1 paper)
- Partner nations
- United StatesNew ZealandNetherlands
In The Last Decade
Cory Iverson
12 papers receiving 590 citations
Peers
Comparison fields: 5 of 74
- Nephrology 117
- Aging 10
- Molecular Biology 370
- Pathology and Forensic Medicine 69
- Cell Biology 50
Countries citing papers authored by Cory Iverson
This map shows the geographic impact of Cory Iverson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Cory Iverson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Cory Iverson more than expected).
Fields of papers citing papers by Cory Iverson
This network shows the impact of papers produced by Cory Iverson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Cory Iverson. The network helps show where Cory Iverson may publish in the future.
Co-authors
The 25 scholars most cited alongside Cory Iverson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2004 | 204 | |
| 2 | 2009 | 156 | |
| 3 | 2016 | 107 | |
| 4 | 2013 | 46 | |
| 5 | 2018 | 32 | |
| 6 | 2018 | 24 | |
| 7 | 2015 | 16 | |
| 8 | 2011 | 10 | |
| 9 | RDEA119: A potent and highly selective MEK inhibitor for the treatment of cancer | 2007 | 3 |
| 10 | 2010 | 2 | |
| 11 | 2008 | 2 | |
| 12 | 2011 | 1 | |
| 13 | 2016 | 0 |
About Cory Iverson
Cory Iverson is a scholar working on Molecular Biology, Oncology, Nephrology, Biotechnology and Hepatology, having authored 13 papers that have together received 603 indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (5 papers), Gout, Hyperuricemia, Uric Acid (3 papers), Cancer Research and Treatments (2 papers), Folate and B Vitamins Research (1 paper), Angiogenesis and VEGF in Cancer (1 paper), Ubiquitin and proteasome pathways (1 paper), Fatty Acid Research and Health (1 paper) and Cancer Genomics and Diagnostics (1 paper). The work is most often cited by research in Nephrology (117 citations), Aging (10 citations), Molecular Biology (370 citations), Pathology and Forensic Medicine (69 citations) and Cell Biology (50 citations). Cory Iverson has collaborated with scholars based in United States, New Zealand and Netherlands. Frequent co-authors include Jeffrey N. Miner, Li‐Tain Yeh, Stephanie Chu, John R. Yates, Barry Quart, Scott Anderson, Stephen R. Fairclough, Ted Powers, J. Michael McCaffery and Karen P. Wedaman. Their work appears in journals such as Clinical Cancer Research, Arthritis Research & Therapy, Molecular Cancer Therapeutics, Journal of Clinical Oncology and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.